相似文献
1
Possibilities of immunoprophylaxis and immunotherapy in gut-derived infectious-toxic shock (GITS).
Curr Stud Hematol Blood Transfus. 1992(59):301-23. doi: 10.1159/000429615.
2
Production of human monoclonal antibodies: potential therapeutic use in gut-derived infectious-toxic shock syndromes.
Curr Stud Hematol Blood Transfus. 1992(59):324-47. doi: 10.1159/000429616.
3
[Cytokines and septic shock. New perspectives on its treatment].
An Med Interna. 1993 Dec;10(12):573-5.
4
Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.
Infection. 1991 Nov-Dec;19(6):383-90. doi: 10.1007/BF01726444.
5
Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
Prog Clin Biol Res. 1991;367:141-59.
6
Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
Ann Emerg Med. 1993 Dec;22(12):1871-90. doi: 10.1016/s0196-0644(05)80417-2.
7
Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
Lancet. 1993 Apr 10;341(8850):959-60. doi: 10.1016/0140-6736(93)91250-p.
8
Antibody to endotoxin in the treatment of gram-negative sepsis.
JAMA. 1992 May 6;267(17):2325; author reply 2326. doi: 10.1001/jama.267.17.2325c.
9
Immunological intervention in endotoxin shock.
Prog Clin Biol Res. 1988;272:319-25.
10
Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal.
Infect Dis Clin North Am. 1991 Dec;5(4):915-27.
Zotero 插件